We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-7.85%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.32B
AUM Growth
-$394M
Cap. Flow
-$88.3M
Cap. Flow %
-6.7%
Top 10 Hldgs %
63.8%
Holding
83
New
13
Increased
13
Reduced
16
Closed
22

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$114M
2
AZN icon
AstraZeneca
AZN
+$33.2M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$22.5M
4
ZTS icon
Zoetis
ZTS
+$21.1M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$17.9M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$42.2M
2
BPMC
Blueprint Medicines
BPMC
+$26.3M
3
ALGN icon
Align Technology
ALGN
+$25.1M
4
HRTX icon
Heron Therapeutics
HRTX
+$21.4M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$20.9M

Sector Composition

Rank Sector Weight
1 Healthcare 89.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$248M 18.79%
1,953,077
– –
NTRA icon
2
Natera
NTRA
$37.5B
$126M 9.58%
3,102,960
– –
CINC
3
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$97.8M 7.42%
+5,573,949
New +$114M
VERA icon
4
Vera Therapeutics
VERA
$2.54B
$74.7M 5.67%
3,181,442
+266,666
+9% +$5.74M
JBIO
5
Jade Biosciences
JBIO
$1.22B
$68.9M 5.23%
107,391
– –
QQQ icon
6
PUT
Invesco QQQ Trust
QQQ
$455B
$63.4M 4.82%
175,000
+75,000
+75% +$26.6M
ASND icon
7
Ascendis Pharma A/S
ASND
$16.7B
$58.7M 4.45%
499,824
– –
AZN icon
8
AstraZeneca
AZN
$263B
$36.7M 2.79%
+276,952
New +$33.2M
UTHR icon
9
United Therapeutics
UTHR
$26.3B
$35.7M 2.71%
199,183
+69,429
+54% +$13.2M
IWM icon
10
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$30.8M 2.34%
150,000
– –
YMAB
11
DELISTED
Y-mAbs Therapeutics
YMAB
$26.1M 1.98%
2,194,278
– –
VRTX icon
12
Vertex Pharmaceuticals
VRTX
$121B
$24.8M 1.88%
+95,003
New +$22.5M
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$24.5M 1.86%
232,894
+11,102
+5% +$1.08M
DXCM icon
14
DexCom
DXCM
$27.6B
$20.6M 1.56%
161,060
+31,444
+24% +$3.44M
RGNX icon
15
Regenxbio
RGNX
$623M
$20.4M 1.55%
614,085
-393,996
-39% -$10.9M
ZTS icon
16
Zoetis
ZTS
$31.6B
$20.1M 1.53%
+106,574
New +$21.1M
RETA
17
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$19.7M 1.5%
+602,545
New +$17.9M
SRRA
18
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$18.3M 1.39%
572,297
+360,016
+170% +$10.3M
XBI icon
19
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$18M 1.36%
+200,000
New +$18.5M
ISEE
20
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.2M 1.3%
1,021,211
+222,422
+28% +$3.29M
TVTX icon
21
Travere Therapeutics
TVTX
$5.33B
$17M 1.29%
658,249
-382,609
-37% -$10.2M
GH icon
22
Guardant Health
GH
$19.5B
$15.9M 1.21%
239,995
+7,432
+3% +$509K
CCXI
23
DELISTED
ChemoCentryx, Inc.
CCXI
$14.4M 1.09%
573,684
-157,538
-22% -$4.43M
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$11.5B
$13.6M 1.03%
176,533
+89,211
+102% +$7.46M
NXTC icon
25
NextCure
NXTC
$17.3M
$13M 0.99%
222,655
– –
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2022 Portfolio in Review

As of Q1 2022, Sofinnova Investments held 83 positions worth $1.32B, down 23% from $1.71B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Sofinnova Investments withdrew a net $88.3M in Q1 2022, closing 22 positions and reducing 16 holdings. Its most notable exit was AbbVie, an estimated $42.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 85% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in CinCor Pharma, Inc. Common Stock worth $97.8M.

  • Sofinnova Investments's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 5,573,949 shares worth $97.8M.
  • Sofinnova Investments added most to United Therapeutics in Q1 2022, an estimated $13.2M increase.
  • Sofinnova Investments's biggest Q1 2022 reduction was Heron Therapeutics, cutting an estimated $21.4M.
  • Sofinnova Investments fully exited AbbVie in Q1 2022, selling an estimated $42.2M.
  • Sofinnova Investments's ten largest holdings make up 64% of its $1.32B portfolio in Q1 2022.
  • Sofinnova Investments opened 13 new positions and closed 22 in Q1 2022.
  • Sofinnova Investments's portfolio value fell 23% quarter-over-quarter to $1.32B.

Based on Sofinnova Investments's 13F filing for Q1 2022, filed 16 May 2022.